Link Biologics Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Early Stage VC
- Latest Deal Amount
-
$3.66M
- Investors
-
3
Link Biologics General Information
Description
Developer of a protein biologic designed for people living with inflammatory and degenerative disorders. The company offers a combination of anti-inflammatory and tissue-protecting properties, enabling users with musculoskeletal and ophthalmological diseases to improve daily activities and quality of life.
Contact Information
Website
www.linkbiologics.co.ukCorporate Office
- 124 City Road
- London EC1V 2NX
- England, United Kingdom
Corporate Office
- 124 City Road
- London EC1V 2NX
- England, United Kingdom
Link Biologics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC | 23-Oct-2023 | $3.66M | Completed | Pre-Clinical Trials | ||
| 2. Accelerator/Incubator | 01-Jan-2021 | Completed | Startup | |||
| 1. University Spin-Out | 01-Apr-2020 | Completed | Startup |
Link Biologics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A Preferred |
Link Biologics Patents
Link Biologics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202416087-D0 | Treatment of ocular disorders | Pending | 31-Oct-2024 | ||
| WO-2026093560-A1 | Treatment of ocular disorders | Pending | 31-Oct-2024 | ||
| EP-4281098-A1 | Use of link-tsg6 for the treatment of osteoarthritic pain | Pending | 20-Jan-2021 | ||
| US-20250121028-A1 | Use of link-tsg6 for the treatment of osteoarthritic pain | Pending | 20-Jan-2021 | ||
| US-20150057229-A1 | Method of treating bone disorders using tsg-6 | Active | 06-Mar-2006 | A61K38/1709 |
Link Biologics Signals
Link Biologics Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Théa Open Innovation | Venture Capital | Minority | ||
| Creative Destruction Lab | Accelerator/Incubator | |||
| The University of Manchester | University | Minority |
Link Biologics FAQs
-
When was Link Biologics founded?
Link Biologics was founded in 2020.
-
Where is Link Biologics headquartered?
Link Biologics is headquartered in London, United Kingdom.
-
What is the size of Link Biologics?
Link Biologics has 6 total employees.
-
What industry is Link Biologics in?
Link Biologics’s primary industry is Drug Discovery.
-
Is Link Biologics a private or public company?
Link Biologics is a Private company.
-
What is the current valuation of Link Biologics?
The current valuation of Link Biologics is .
-
What is Link Biologics’s current revenue?
The current revenue for Link Biologics is .
-
How much funding has Link Biologics raised over time?
Link Biologics has raised $3.66M.
-
Who are Link Biologics’s investors?
Théa Open Innovation, Creative Destruction Lab, and The University of Manchester have invested in Link Biologics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process